Stock vs Stock Comparison

ResMed Inc. vs Agilent Technologies, Inc.

RMD wins the Tale of the Tape 8–1.

RMD$186.46
A$137.40

🏆 Tale of the Tape

81
RMDA
27.2%Profitability (Net Margin)18.8%
18.4xValuation (P/E)27.3x
18.6%Efficiency (ROIC)11.8%
7/9Health (Piotroski F)5/9
11.8Safety (Altman Z)4.6
9.8%Growth (Rev YoY)6.7%
0.21Risk (Sharpe 1Y)0.32
0.37xBalance Sheet (D/E)0.89x
5.02%FCF Yield3.41%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.351
252-Day Correlation
0.335
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricRMDA
Market Cap$27.6B$38.2B
P/E Ratio18.4x27.3x
Forward P/E15.6x20.5x
P/B4.26x5.37x
Dividend Yield1.26%0.75%
Beta0.841.22

Quantitative Metrics

MetricRMDA
DCF Fair Value$289.83$50.34
DCF Upside+25.9%-57.1%
Piotroski F7/95/9
Altman Z11.804.57
Beneish M-2.62-2.46
FCF Yield5.02%3.41%
Net Debt/EBITDA-0.3x0.7x
ROIC18.6%11.8%
WACC10.4%12.1%
ROIC – WACC8.2pp-0.3pp
Gross Margin59.4%52.4%
Net Margin27.2%18.8%
Rev Growth YoY9.8%6.7%
Sharpe (1Y)0.210.32
Max Drawdown 3Y
FCF Payout Ratio19%24%

RMD Price

Loading chart...

A Price

Loading chart...

ETF Exposure

RMD found in:

IHI4.52%
XHE1.49%
VOT0.73%
XLV0.57%
VHT0.51%
VO0.32%
ONEV0.21%
RSP0.20%
ONEO0.16%
SCHG0.14%
VIG0.14%
VUG0.10%
IWD0.08%
QUS0.07%
VONV0.07%
ESGV0.07%
SPLG0.06%
SCHX0.06%
IVV0.06%
SCHB0.06%
ITOT0.05%
VONE0.05%
VOO0.05%
SPYG0.05%
SPY0.05%
SPYV0.05%
SPTM0.05%
URTH0.04%
VTI0.04%
ACWI0.04%
DGRW0.04%
IWF0.03%
VONG0.02%

A found in:

MOAT1.31%
VOT0.77%
XLV0.61%
VHT0.53%
VO0.33%
ONEV0.29%
RSP0.18%
VIG0.15%
VTV0.13%
SCHV0.12%
SPYV0.11%
IWD0.11%
VONV0.10%
ONEO0.09%
ESGV0.07%
QUS0.07%
SPLG0.07%
IVV0.07%
ITOT0.06%
SCHX0.06%
SCHB0.05%
SPY0.05%
VTI0.05%
VOO0.05%
VONE0.05%
SPTM0.05%
URTH0.04%
ACWI0.04%
DGRW0.04%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

RMD vs A: Head-to-Head Analysis

ResMed Inc. (RMD) and Agilent Technologies, Inc. (A) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, RMD leads 8–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, RMD generates a return on invested capital (ROIC) of 18.6% compared to A's 11.8%. This suggests RMD is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between RMD and A is 0.351, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

RMD appears in 33 ETFs tracked by SecuritiesDB, while A appears in 29 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, RMD or A?

Our quantitative analysis compares RMD and A across nine fundamental dimensions. RMD wins the Tale of the Tape 8–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are RMD and A correlated?

The 252-day correlation between RMD and A is 0.351. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.